Contineum Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Revenue | — | $0 | $50.0M |
| Operating income | -$68.1M | -$50.9M | $16.1M |
| Operating expenses | $68.1M | $50.9M | $33.9M |
| Cash from operations | -$55.3M | -$32.8M | $19.3M |
| Capital expenditure | $231,000 | $514,000 | $414,000 |
| Free cash flow | -$55.5M | -$33.4M | $18.9M |
| Share repurchases | — | $0 | $28,000 |
| Total assets | $276.6M | $212.8M | $130.4M |
| Total liabilities | $15.7M | $14.8M | $5.7M |
Shares outstanding 37.4M · Free float 85.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.